AOC-1020 by Avidity Biosciences for Facioscapulohumeral Muscular Dystrophy (FSHD): Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AOC-1020 overview

AOC-1020 is under development for the treatment of facioscapulohumeral muscular dystrophy (FSHD). It is administered through intravenous route. The drug candidate is an antibody oligonucleotide conjugate (AOC) comprising monoclonal antibody that binds to cells expressing transferrin receptor 1 (TfR1) conjugated with a siRNA targeting DUX4 mRNA. It is being developed based on antibody oligonucleotide conjugate (AOC) platform.

Avidity Biosciences overview

Avidity Biosciences is a biotech company that develops antibody oligonucleotide conjugates (AOCs). The company product pipeline include AOC 1001, AOC 1044 and AOC 1020. Its pipeline treats myotonic dystrophy type 1 (DM1), duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity Biosciences carries out AOC components such as monoclonal, linker, siRNA and PMO. The company has research collaborations with leading pharma companies, to discover antibody-based drug candidates against various therapeutic targets. Avidity Biosciences is headquartered in San Diego, California, the US.

For a complete picture of AOC-1020’s drug-specific PTSR and LoA scores, buy the report here.

Sign up for our daily news round-up!

Give your business an edge with our leading industry insights.